Home/Pipeline/PRGN-3006 (UltraCAR-T)

PRGN-3006 (UltraCAR-T)

Acute Myeloid Leukemia (AML)

Phase 1bActive

Key Facts

Indication

Acute Myeloid Leukemia (AML)

Phase

Phase 1b

Status

Active

Company

Precigen

About Precigen

Precigen is a commercial-stage biopharmaceutical company focused on developing precision gene and cell therapies for immuno-oncology, autoimmune disorders, and infectious diseases. The company achieved a critical inflection point with the FDA approval of PAPZIMEOS in August 2025 for recurrent respiratory papillomatosis (RRP). Its strategy is built on two proprietary technology platforms—AdenoVerse® for viral vector gene delivery and UltraCAR-T® for next-generation cell therapy—designed to overcome key limitations in the field and create a sustainable pipeline of advanced therapeutics.

View full company profile

Therapeutic Areas

Immuno-oncology Autoimmune Disorders Infectious Diseases

Other Acute Myeloid Leukemia (AML) Drugs

Drug	Company	Phase	Status
Mipletamig (APVO436)	Aptevo Therapeutics	Phase 1/2	Active
lomonitinib	Lomond Therapeutics	IND-Enabling	Active
lonitoclax	Lomond Therapeutics	Phase 1	Active
Menin Inhibitor	Lomond Therapeutics	Discovery	Active
AB8939	AB Science	Phase 1	Active
Small-Molecule Therapeutic	AIkido Labs	Pre-clinical	Active
ADI-PEG 20 (pegargiminase)	Polaris Pharma	Phase 1	Active
ACD-101	Advanced Cellular Dynamics	Phase 1	IND-Enabling
ABD-3001	Advanced Biodesign	Phase 1	Active (trial began early 2023)
HC-7366	HiberCell	Phase 1b	Active - Monotherapy & in combination with venetoclax and azacitidine
oNKord® (Inaleucel)	Glycostem	Phase 1/2a	Active
M2T™ Program (unspecified)	Leukogene Therapeutics	Preclinical	Active